Aripiprazole, Abilify Maintena Collaborative Clinical Protocol
NCT ID: NCT02717130
Last Updated: 2020-04-13
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Clinical Phase
NA
Total Enrollment
9 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-06-08
Study Completion Date
2017-05-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
NCT00211302
Schizophrenia
Schizoaffective Disorder
TERMINATED
NA
Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia
NCT00712270
Schizophrenia
TERMINATED
PHASE4
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
NCT02237417
Schizophrenia
COMPLETED
PHASE4
Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
NCT00211380
Schizophrenia
Schizoaffective Disorder
TERMINATED
NA
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
NCT00325689
Schizophrenia
Schizoaffective Disorder
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is an open-label, multi-center, longitudinal, within-subject comparison study of the effects of aripiprazole once monthly on 30-, 90-, and 180-day psychiatric re-hospitalization rates following hospital discharge in subjects with schizophrenia compared with prior psychiatric hospitalization rates while on oral antipsychotics.
Prospective subjects will undergo screening for eligibility for entry into the study while hospitalized for symptoms due to schizophrenia.
Prospective subjects will be hospitalized for the necessary length of time as determined by the assigned treatment provider as clinically indicated, per the current standard of care. To be eligible, the anticipated duration of hospitalization should be long enough to accommodate the screening procedures, the 3-day Oral Tolerability Phase (if applicable), and initiation of treatment with aripiprazole once monthly.
During the Screening Period, subjects can be treated with any oral antipsychotic medication of the clinician's choice, with the exception of clozapine and olanzapine. However, oral olanzapine is permitted during the Screening Period only for subjects who are eligible for Phase A. Following the Screening Period, subjects who have no history of aripiprazole use will be entered into Phase A, the Oral Tolerability Phase. Subjects from Phase A that demonstrate tolerability to aripiprazole will then be entered into Phase B (i.e., the Treatment Phase). Subjects who already have a history of tolerating at least three consecutive oral doses of aripiprazole will be entered directly into Phase B. All eligible subjects will eventually enter Phase B.
Subjects who meet the inclusion and exclusion criteria and have no history of oral aripiprazole use will enter Phase A after the Screening Period while still hospitalized. Subjects in Phase A will be administered oral aripiprazole, as indicated in the product labeling, to determine tolerability. Dosage will be based on symptoms and the judgment of the investigator. The dose of oral aripiprazole may be titrated as needed. Prior antipsychotic medications will be tapered off and discontinued during the Screening Period and Phase A as clinically appropriate.
During Phase A, tolerability to oral aripiprazole will be evaluated daily for a minimum of 3 days using safety and tolerability measures (i.e., AIMS, BARS, and SAS) in conjunction with clinical judgment. If the subject shows tolerability to the oral aripiprazole, the Phase B baseline/Day 1 should occur with the first aripiprazole once monthly injection given immediately after the Phase B baseline/Day1 assessments. If a subject is unable to tolerate oral aripiprazole during the tolerability assessment in Phase A, he or she will be withdrawn from the study.
During Phase B, the subject will receive the first aripiprazole once monthly intramuscular (IM) injection, in conjunction with the first of 14 doses of concomitant oral aripiprazole, as indicated in the product labeling, after the baseline data are collected.
All subjects must attend scheduled visits at the Baseline Visit and Weeks 2, 4, 8, 12, 16, 20, and 24, totaling 180 days. Aripiprazole once monthly injections will occur at the Baseline Visit and every 28 ( -2, +5) days at Weeks 4, 8, 12, 16, 20, and 24, totaling seven injections. After the initial injection of 400 mg, the monthly dosage can be decreased to 300 mg, based on the clinical judgment of the investigator. All aripiprazole once monthly injections will be administered based on the investigator's judgment and the prescribing information.
For subjects who are psychiatrically stabilized and discharged prior to the completion of the required 14-day course of oral aripiprazole, a pre-discharge assignment will be given to a community support worker (CSW). The CSW will maintain regular contact with the subject until the first outpatient visit in Phase B (Week 2), when oral aripiprazole will be discontinued. Regular contact is defined as no less than weekly, but can be more frequent depending on the clinical judgment of the CSW and outpatient treatment team. Following the Week 2 Visit, subjects will have contact with their assigned CSW based on routine clinical care. Contact with the CSW can be in person or by telephone, as clinically appropriate.
Note: All long-acting antipsychotics are excluded from use during the study; however, aripiprazole once monthly is allowed
Prospective subjects will undergo screening for eligibility for entry into the study while hospitalized for symptoms due to schizophrenia.
Prospective subjects will be hospitalized for the necessary length of time as determined by the assigned treatment provider as clinically indicated, per the current standard of care. To be eligible, the anticipated duration of hospitalization should be long enough to accommodate the screening procedures, the 3-day Oral Tolerability Phase (if applicable), and initiation of treatment with aripiprazole once monthly.
During the Screening Period, subjects can be treated with any oral antipsychotic medication of the clinician's choice, with the exception of clozapine and olanzapine. However, oral olanzapine is permitted during the Screening Period only for subjects who are eligible for Phase A. Following the Screening Period, subjects who have no history of aripiprazole use will be entered into Phase A, the Oral Tolerability Phase. Subjects from Phase A that demonstrate tolerability to aripiprazole will then be entered into Phase B (i.e., the Treatment Phase). Subjects who already have a history of tolerating at least three consecutive oral doses of aripiprazole will be entered directly into Phase B. All eligible subjects will eventually enter Phase B.
Subjects who meet the inclusion and exclusion criteria and have no history of oral aripiprazole use will enter Phase A after the Screening Period while still hospitalized. Subjects in Phase A will be administered oral aripiprazole, as indicated in the product labeling, to determine tolerability. Dosage will be based on symptoms and the judgment of the investigator. The dose of oral aripiprazole may be titrated as needed. Prior antipsychotic medications will be tapered off and discontinued during the Screening Period and Phase A as clinically appropriate.
During Phase A, tolerability to oral aripiprazole will be evaluated daily for a minimum of 3 days using safety and tolerability measures (i.e., AIMS, BARS, and SAS) in conjunction with clinical judgment. If the subject shows tolerability to the oral aripiprazole, the Phase B baseline/Day 1 should occur with the first aripiprazole once monthly injection given immediately after the Phase B baseline/Day1 assessments. If a subject is unable to tolerate oral aripiprazole during the tolerability assessment in Phase A, he or she will be withdrawn from the study.
During Phase B, the subject will receive the first aripiprazole once monthly intramuscular (IM) injection, in conjunction with the first of 14 doses of concomitant oral aripiprazole, as indicated in the product labeling, after the baseline data are collected.
All subjects must attend scheduled visits at the Baseline Visit and Weeks 2, 4, 8, 12, 16, 20, and 24, totaling 180 days. Aripiprazole once monthly injections will occur at the Baseline Visit and every 28 ( -2, +5) days at Weeks 4, 8, 12, 16, 20, and 24, totaling seven injections. After the initial injection of 400 mg, the monthly dosage can be decreased to 300 mg, based on the clinical judgment of the investigator. All aripiprazole once monthly injections will be administered based on the investigator's judgment and the prescribing information.
For subjects who are psychiatrically stabilized and discharged prior to the completion of the required 14-day course of oral aripiprazole, a pre-discharge assignment will be given to a community support worker (CSW). The CSW will maintain regular contact with the subject until the first outpatient visit in Phase B (Week 2), when oral aripiprazole will be discontinued. Regular contact is defined as no less than weekly, but can be more frequent depending on the clinical judgment of the CSW and outpatient treatment team. Following the Week 2 Visit, subjects will have contact with their assigned CSW based on routine clinical care. Contact with the CSW can be in person or by telephone, as clinically appropriate.
Note: All long-acting antipsychotics are excluded from use during the study; however, aripiprazole once monthly is allowed
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Schizophrenia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aripiprazole (Abilify Maintena)
Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
Group Type
EXPERIMENTAL
Aripiprazole
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aripiprazole
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are able to provide written informed consent.
* Are male and female subjects 18 to 65 years of age, inclusive, at time of informed consent
* Have a current diagnosis of schizophrenia as defined by DSM-5 criteria and a history of the illness for at least 6 months prior to screening from a reliable source (e.g., subject, family member, friend, caregiver, healthcare provider, or medical records)
* Present at one of the selected inpatient units with acute psychotic symptoms for hospitalization at study entry
* Have a clinically indicated need for a change in current antipsychotic therapy
* Are on Medicaid with searchable claims data
* Have at least one inpatient psychiatric hospitalization or psychiatric ED visit within the 6 months prior to screening
* Have been previously prescribed oral antipsychotic treatment for the 6 consecutive months prior to screening
* Have a history of response to antipsychotic treatment, with no history of clozapine treatment
* Are able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, aripiprazole once monthly injection, and discontinuation of prohibited concomitant medications
* Are able to read and understand the written word in order to complete subject-reported outcomes measures
* Are willing to accept a monthly injection
* Are male and female subjects who are surgically sterile (i.e., have undergone orchiectomy or hysterectomy, respectively); female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to use an approved form of birth control during study participation
* Are male and female subjects 18 to 65 years of age, inclusive, at time of informed consent
* Have a current diagnosis of schizophrenia as defined by DSM-5 criteria and a history of the illness for at least 6 months prior to screening from a reliable source (e.g., subject, family member, friend, caregiver, healthcare provider, or medical records)
* Present at one of the selected inpatient units with acute psychotic symptoms for hospitalization at study entry
* Have a clinically indicated need for a change in current antipsychotic therapy
* Are on Medicaid with searchable claims data
* Have at least one inpatient psychiatric hospitalization or psychiatric ED visit within the 6 months prior to screening
* Have been previously prescribed oral antipsychotic treatment for the 6 consecutive months prior to screening
* Have a history of response to antipsychotic treatment, with no history of clozapine treatment
* Are able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, aripiprazole once monthly injection, and discontinuation of prohibited concomitant medications
* Are able to read and understand the written word in order to complete subject-reported outcomes measures
* Are willing to accept a monthly injection
* Are male and female subjects who are surgically sterile (i.e., have undergone orchiectomy or hysterectomy, respectively); female subjects who have been postmenopausal for at least 12 consecutive months; or male and female subjects who agree to use an approved form of birth control during study participation
Exclusion Criteria
* Has a current DSM-5 diagnosis other than schizophrenia, including schizophreniform disorder, schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also excluded are subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
* Prisoners or subjects who are involuntarily incarcerated, or have been incarcerated in the past 7 months for any reason
* Require potent cytochrome P450 (CYP)2D or CYP3A4 inhibitors or CYP3A4 inducers
* Are allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones or has a history of hypersensitivity to antipsychotic agents
* Have received electroconvulsive therapy within the 6 months prior to screening
* Have a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator
* Have current diagnosis of diabetes or known fasting triglyceride levels consistent with risk for pancreatitis
* Meets DSM-5 criteria for current substance use disorder within 3 months prior to screening
* Received treatment with long-acting injectable antipsychotics (e.g., haloperidol decanoate, fluphenazine decanoate, risperidone long-acting injection \[Risperdal Consta®\], paliperidone palmitate extended-release injectable suspension \[Invega® Sustenna®\], olanzapine for extended-release injectable suspension \[Zyprexa® Relprevv™\]), in which the last dose was within 7 months prior to screening
* Have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on Question 4 or Question 5 within the last 30 days on the baseline version of the C-SSRS
* Have a history or evidence of a medical condition that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the study, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease as determined by the clinical judgment of the investigator
* Have results from one or more of the following laboratory test, vital sign, and ECG tests at screening that are exclusionary (laboratory testing and ECGs will be performed locally): Platelets ≤ 75,000/mm3; Hemoglobin ≤ 9 g/dL; Fasting blood glucose \> 126 mg/dL or HbA1c \> 7.0%; Fasting triglyceride \> 500 mg/dL; Neutrophils, absolute ≤ 1000/mm3; Aspartate transaminase (AST) \> 3x ULN; Alanine transaminase (ALT) \> 3x ULN; Creatinine ≥ 2 mg/dL; Diastolic blood pressure \> 105 mmHg; QTc \> 475 msec on either the QTcB (Bazett) or QTcF (Fridericia) corrections on ECG, confirmed by a second tracing; Any other abnormal laboratory tests, vital sign results, or ECG findings that, in the judgment of the investigator, are medically significant and would affect the safety of the subject or the interpretation of the study results. Abnormal results for laboratory parameters or vital signs should be repeated to ensure reproducibility of the abnormality before excluding a subject based on the criteria noted above.
* Have been previously enrolled in an aripiprazole once monthly clinical study
* Have participated in any clinical study with an investigational agent within the past 30 days
* Are pregnant or lactating
* Prisoners or subjects who are involuntarily incarcerated, or have been incarcerated in the past 7 months for any reason
* Require potent cytochrome P450 (CYP)2D or CYP3A4 inhibitors or CYP3A4 inducers
* Are allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones or has a history of hypersensitivity to antipsychotic agents
* Have received electroconvulsive therapy within the 6 months prior to screening
* Have a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia as assessed by the investigator
* Have current diagnosis of diabetes or known fasting triglyceride levels consistent with risk for pancreatitis
* Meets DSM-5 criteria for current substance use disorder within 3 months prior to screening
* Received treatment with long-acting injectable antipsychotics (e.g., haloperidol decanoate, fluphenazine decanoate, risperidone long-acting injection \[Risperdal Consta®\], paliperidone palmitate extended-release injectable suspension \[Invega® Sustenna®\], olanzapine for extended-release injectable suspension \[Zyprexa® Relprevv™\]), in which the last dose was within 7 months prior to screening
* Have a significant risk of committing suicide based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on Question 4 or Question 5 within the last 30 days on the baseline version of the C-SSRS
* Have a history or evidence of a medical condition that would expose them to an undue risk of a significant AE or interfere with assessments of safety or efficacy during the course of the study, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or immunologic disease as determined by the clinical judgment of the investigator
* Have results from one or more of the following laboratory test, vital sign, and ECG tests at screening that are exclusionary (laboratory testing and ECGs will be performed locally): Platelets ≤ 75,000/mm3; Hemoglobin ≤ 9 g/dL; Fasting blood glucose \> 126 mg/dL or HbA1c \> 7.0%; Fasting triglyceride \> 500 mg/dL; Neutrophils, absolute ≤ 1000/mm3; Aspartate transaminase (AST) \> 3x ULN; Alanine transaminase (ALT) \> 3x ULN; Creatinine ≥ 2 mg/dL; Diastolic blood pressure \> 105 mmHg; QTc \> 475 msec on either the QTcB (Bazett) or QTcF (Fridericia) corrections on ECG, confirmed by a second tracing; Any other abnormal laboratory tests, vital sign results, or ECG findings that, in the judgment of the investigator, are medically significant and would affect the safety of the subject or the interpretation of the study results. Abnormal results for laboratory parameters or vital signs should be repeated to ensure reproducibility of the abnormality before excluding a subject based on the criteria noted above.
* Have been previously enrolled in an aripiprazole once monthly clinical study
* Have participated in any clinical study with an investigational agent within the past 30 days
* Are pregnant or lactating
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
Sponsor Role
collaborator
University of Missouri-Columbia
OTHER
Sponsor Role
collaborator
University of Missouri, Kansas City
OTHER
Sponsor Role
collaborator
Burrell Behavioral Health
OTHER
Sponsor Role
collaborator
Florida Atlantic University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Newcomer, MD
Role: PRINCIPAL_INVESTIGATOR
Florida Atlantic University
Ginger Nicol, MD
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Missouri
Columbia, Missouri, United States
Site Status
University of Missouri
Kansas City, Missouri, United States
Site Status
Burrell Behavioral Health
Springfield, Missouri, United States
Site Status
Washington University
St Louis, Missouri, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17-29. doi: 10.1093/oxfordjournals.schbul.a006920.
Reference Type
BACKGROUND
Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry. 2000 Apr;34(2):221-36. doi: 10.1080/j.1440-1614.2000.00728.x.
Reference Type
BACKGROUND
Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl. 2009 Nov;52:S37-42. doi: 10.1192/bjp.195.52.s37.
Reference Type
BACKGROUND
Barnes TR, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P; UK Prescribing Observatory for Mental Health. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand. 2008 Jul;118(1):26-33. doi: 10.1111/j.1600-0447.2008.01203.x.
Reference Type
BACKGROUND
Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002 Oct;106(4):286-90. doi: 10.1034/j.1600-0447.2002.02437.x.
Reference Type
BACKGROUND
Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, van Os J. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000 Sep;102(3):203-10. doi: 10.1034/j.1600-0447.2000.102003203.x.
Reference Type
BACKGROUND
Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67 Suppl 5:3-8.
Reference Type
BACKGROUND
Thornicroft G, Farrelly S, Szmukler G, Birchwood M, Waheed W, Flach C, Barrett B, Byford S, Henderson C, Sutherby K, Lester H, Rose D, Dunn G, Leese M, Marshall M. Clinical outcomes of Joint Crisis Plans to reduce compulsory treatment for people with psychosis: a randomised controlled trial. Lancet. 2013 May 11;381(9878):1634-41. doi: 10.1016/S0140-6736(13)60105-1. Epub 2013 Mar 26.
Reference Type
BACKGROUND
Burns T, Rugkasa J, Molodynski A, Dawson J, Yeeles K, Vazquez-Montes M, Voysey M, Sinclair J, Priebe S. Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial. Lancet. 2013 May 11;381(9878):1627-33. doi: 10.1016/S0140-6736(13)60107-5. Epub 2013 Mar 26.
Reference Type
BACKGROUND
Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010 Nov;35(12):2367-77. doi: 10.1038/npp.2010.111. Epub 2010 Aug 4.
Reference Type
BACKGROUND
Olivares JM, Rodriguez-Martinez A, Buron JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy. 2008;6(1):41-53. doi: 10.2165/00148365-200806010-00004.
Reference Type
BACKGROUND
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002 Sep;63(9):763-71. doi: 10.4088/jcp.v63n0903.
Reference Type
BACKGROUND
Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul;60(7):681-90. doi: 10.1001/archpsyc.60.7.681.
Reference Type
BACKGROUND
Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003 Dec;6(4):325-37. doi: 10.1017/S1461145703003651.
Reference Type
BACKGROUND
Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry. 2007 Oct;22(7):433-43. doi: 10.1016/j.eurpsy.2007.03.002. Epub 2007 Jun 7.
Reference Type
BACKGROUND
Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, Beuzen JN, Carson W, Corey-Lisle PK, Falissard B, Jody DN, Kujawa MJ, L'italien G, Marcus RN, McQuade RD, Ray S, Van Peborgh P; IAQ Validation Study Group. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res. 2005 Sep 15;136(2-3):211-21. doi: 10.1016/j.psychres.2005.05.006.
Reference Type
BACKGROUND
Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Swanink R, Iwamoto T; Aripoprazole Study Group. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005 Sep;187:235-42. doi: 10.1192/bjp.187.3.235.
Reference Type
BACKGROUND
Schulte RF, Boesiger P. ProFit: two-dimensional prior-knowledge fitting of J-resolved spectra. NMR Biomed. 2006 Apr;19(2):255-63. doi: 10.1002/nbm.1026.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/Measure-ACO-8-Readmission.pdf
ACO #8-Risk Standardized All Condition Readmission
http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/OutcomeMeasures.html
Outcome Measures. Baltimore: Centers for Medicare \& Medicaid Services;
http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html
Redmissions Reduction Program
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
031-104-0014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
NCT00508157
TERMINATED
PHASE4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00177008
COMPLETED
PHASE4
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
NCT02501109
COMPLETED
PHASE1
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
NCT00580125
COMPLETED
PHASE2
Aripiprazole in Adolescents With Schizophrenia
NCT00102063
COMPLETED
PHASE3
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00167817
COMPLETED
PHASE4
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
NCT00320671
COMPLETED
PHASE4
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
NCT02435836
TERMINATED
PHASE3
Aripiprazole Once-monthly in Patients With Schizophrenia
NCT01959035
COMPLETED
PHASE3
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
NCT04203056
TERMINATED
PHASE4
Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
NCT01149655
COMPLETED
PHASE3
Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia
NCT02282085
UNKNOWN
PHASE4
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
NCT03345979
COMPLETED
PHASE3
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
NCT00292409
COMPLETED
PHASE3
Aripiprazole Augmentation Therapy in Treatment-resistant Depression
NCT00276978
WITHDRAWN
PHASE3
Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
NCT00374348
COMPLETED
NA
A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices
NCT00237939
COMPLETED
PHASE3
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
NCT06589817
NOT_YET_RECRUITING
PHASE3
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
NCT00283179
COMPLETED
PHASE3
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
NCT03289026
COMPLETED
PHASE4
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
NCT01795547
COMPLETED
PHASE3
Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
NCT01683058
COMPLETED
PHASE3
Aripiprazole Treatment of the Prodrome
NCT00169949
TERMINATED
NA
The New Strategy for Pharmacological Treatment in People With Schizophrenia
NCT00352339
UNKNOWN
PHASE4